Skip to main content
Equibles

PPLPHARMA · Piramal Pharma Limited

Use PPLPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PPLPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
244.54 INR -0.53 (-0.22%) At close · Nov 13
Rebalance outlook locked
Market Cap
325.57B INR
Shares
1.33B
Volume · Nov 13 2.89M Avg daily vol (3M) 6.23M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close244.54 INR Open245.00 INR Day241.03–248.99 INR 52W close133.27–246.37 INR Avg vol 30d8.5M Last earningsOct 28, 2026 DataOct 2022–Nov 2026

Latest documents

2026
Oct 28
Earnings call
FY27 revenue growth guidance raised to approximately 19% to 20%

Paramil Pharma Ltd upgraded FY27 annual guidance to approximately 19% to 20% revenue growth, with EBITDA expected to grow faster than revenue. Q2 revenue grew 28% year-on-year to 2,617 crores, while EBITDA rose 72% to 385 crores.

3 source passages
Paramil Pharma Ltd In Q2, revenue grew by 28% year-on-year to 2,617 crores, while EBITDA increased 72% to 385 crores. Given this broad-based performance and outlook for the second half, we're upgrading our FY27 annual guidance with earlier guidance to early to mid-teens revenue growth with EBITDA to grow faster than revenue. We now expect an annual revenue growth of approximately 19% to 20% with a meaningful higher growth and profitability. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲12.5% 22.04B INR 36.80M INR '25 Q3 ▲7.9% 27.54B INR 1.53B INR '25 Q4 ▼0.9% 19.34B INR −817.00M INR '26 Q1 ▼8.8% 20.44B INR −992.20M INR '26 Q2 ▼2.9% 21.40B INR −1.36B INR '26 Q3 ▼0.1% 27.52B INR −88.20M INR '26 Q4 ▲17.4% 22.70B INR −693.90M INR '27 Q1 LATEST ▲28.1% 26.17B INR 55.80M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 133.27 INR Now 244.54 INR · 98% Range high 246.37 INR
vs 200-day avg +35% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:PPLPHARMA +2.2% +25.8% +39.2% +2.4% +42.0%

Exchange listing

Market
XNSE
Ticker
PPLPHARMA
ISIN
INE0DK501011
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.piramalpharma.com/
Investor relations
https://www.piramalpharma.com/financial-reports

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2025-07-16 0.14 INR
2024-07-12 0.11 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-10-28 Audio Transcript
    Earnings Call
  • Earnings call · Q1 2027 2026-07-30
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-04-29
    Earnings Call for the Quarter Ended March 31, 2026